Trials
2 active
4 in total · 3 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)”In the company’s words, NCT05142696 on ClinicalTrials.gov
- Main trialPhase 1/2
- “This study aims to establish a safe and well tolerated dose of \[177Lu\]Lu-DOTA-TATE in combination with carboplatin, etoposide and atezolizumab in this setting and to assess preliminary efficacy of this combination treatment versus the combination of carboplatin, etoposide, and atezolizumab.The study will be essential to assess a new potential therapeutic option in participants with this aggressive cancer type.”In the company’s words, NCT05142696 on ClinicalTrials.gov
- Other names
- AAA501
Other drugs for Extensive Stage Small Cell Lung Cancer
- PembrolizumabMerck & Co. · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- Nanocrystalline Megestrol AcetateChangchun GeneScience Pharmaceutical Co., Ltd. · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- Tambotatug pelitecanMediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- ZG006Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 3
Coming up1
- 7 Mar 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 17 NovStatus changed: Active, not recruiting to Terminated · ClinicalTrials.gov NCT06379217
- 17 NovCompletion date moved: 2026-10-09 to 2026-10-16 · ClinicalTrials.gov NCT06379217
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 7 Mar 2028 | A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab | |
| Phase 1Active, not recruiting | 3 Dec 2025 | A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent. | |
| Phase 3Completed | 27 Dec 2024 | A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan | |
| Phase 1Terminated | 16 Oct 2026 | NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026